{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:02:10Z","timestamp":1750737730497,"version":"3.41.0"},"reference-count":89,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016183","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T10:21:44Z","timestamp":1750674104000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myosin inhibitors for treatment of hypertrophic cardiomyopathy"],"prefix":"10.1002","volume":"2025","author":[{"given":"Samuel","family":"Quill","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science; University College London; London UK"},{"name":"Department of Cardiology; Amsterdam University Medical Center; Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad S","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Cardiology; Amsterdam University Medical Center; Amsterdam Netherlands"},{"name":"Heart Center, Academic Medical Center; Amsterdam University Medical Center; Amsterdam Netherlands"},{"name":"European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart; Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folkert W","family":"Asselbergs","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science; University College London; London UK"},{"name":"Heart Center, Academic Medical Center; Amsterdam University Medical Center; Amsterdam Netherlands"},{"name":"European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart; Amsterdam Netherlands"},{"name":"Institute of Health Informatics; University College London; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie","family":"Bezzina","sequence":"additional","affiliation":[{"name":"Heart Center, Academic Medical Center; Amsterdam University Medical Center; Amsterdam Netherlands"},{"name":"European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart; Amsterdam Netherlands"},{"name":"Heart Center; Department of Experimental Cardiology, Amsterdam Academic Medical Center; Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science; University College London; London UK"},{"name":"Barts Heart Centre, St Bartholomew's Hospital; University College London and Inherited Cardiac Diseases Unit; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda","family":"van der Velden","sequence":"additional","affiliation":[{"name":"Heart Center, Academic Medical Center; Amsterdam University Medical Center; Amsterdam Netherlands"},{"name":"European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart; Amsterdam Netherlands"},{"name":"Heart Center, Department of Physiology and Department of Experimental Cardiology; Amsterdam UMC; Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amand F","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science; University College London; London UK"},{"name":"Department of Cardiology; Amsterdam University Medical Center; Amsterdam Netherlands"},{"name":"European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart; Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD016183-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016183-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.amjcard.2023.10.032","article-title":"Genetic testing in hypertrophic cardiomyopathy","volume":"212","author":"Ireland","year":"2024","journal-title":"American Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD016183-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/gim.2014.205","article-title":"Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity","volume":"17","author":"Alfares","year":"2015","journal-title":"Genetics in Medicine"},{"issue":"30","key":"10.1002\/14651858.CD016183-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1093\/eurheartj\/ehae421","article-title":"Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice","volume":"45","author":"Lopes","year":"2024","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD016183-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jacc.2021.07.017","article-title":"Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy","volume":"78","author":"Marvao","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD016183-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jacc.2020.06.011","article-title":"Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers","volume":"76","author":"Lorenzini","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD016183-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/JAHA.122.028974","article-title":"Is hypertrophic cardiomyopathy always a familial and inherited disease?","volume":"12","author":"Bonaventura","year":"2023","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD016183-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/CIRCGENETICS.116.001620","article-title":"Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications","volume":"10","author":"Ingles","year":"2017","journal-title":"Circulation: Cardiovascular Genetics"},{"issue":"12","key":"10.1002\/14651858.CD016183-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD016183-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"European Journal of Heart Failure"},{"issue":"5","key":"10.1002\/14651858.CD016183-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1161\/JAHA.117.006657","article-title":"Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy","volume":"7","author":"Lu","year":"2018","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"10.1002\/14651858.CD016183-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/CIRCRESAHA.110.223842","article-title":"Invited review: the myosins: exploration of the development of our current understanding of these mutations in the motor","volume":"111","author":"Moore","year":"2012","journal-title":"Circulation Research"},{"issue":"23","key":"10.1002\/14651858.CD016183-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"7309","DOI":"10.1007\/s00018-021-03971-y","article-title":"Alpha and beta myosin isoforms and human atrial and ventricular contraction","volume":"78","author":"Walklate","year":"2021","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"7","key":"10.1002\/14651858.CD016183-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circulation Research"},{"issue":"476","key":"10.1002\/14651858.CD016183-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"eaat1199","DOI":"10.1126\/scitranslmed.aat1199","article-title":"Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin: implications for therapy","volume":"11","author":"Toepfer","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"44","key":"10.1002\/14651858.CD016183-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD016183-BIB0017|cit17","volume-title":"StatPearls Publishing [Internet]","author":"Bello","year":"2024"},{"issue":"6","key":"10.1002\/14651858.CD016183-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41569-022-00682-0","article-title":"Targeting the sarcomere in inherited cardiomyopathies","volume":"19","author":"Lehman","year":"2022","journal-title":"Nature Reviews Cardiology"},{"issue":"19","key":"10.1002\/14651858.CD016183-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6273","key":"10.1002\/14651858.CD016183-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD016183-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41598-022-26630-z","article-title":"Effects of aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy","volume":"13","author":"Sharpe","year":"2023","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1002\/14651858.CD016183-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy","volume":"320","author":"Awinda","year":"2021","journal-title":"American Journal of Physiology \u2013 Heart and Circulatory Physiology"},{"key":"10.1002\/14651858.CD016183-BIB0023|cit23","unstructured":"A study of mavacamten in non-obstructive hypertrophic cardiomyopathy (ODYSSEY-HCM) https:\/\/www.clinicaltrials.gov\/study\/NCT05582395"},{"key":"10.1002\/14651858.CD016183-BIB0024|cit24","unstructured":"Phase 3 trial to evaluate the efficacy and safety of aficamten compared to placebo in adults with symptomatic nHCM (ACACIA-HCM) https:\/\/clinicaltrials.gov\/study\/NCT06081894"},{"issue":"2","key":"10.1002\/14651858.CD016183-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","article-title":"Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy: design, rationale, and baseline characteristics of ODYSSEY-HCM","volume":"13","author":"Desai","year":"2025","journal-title":"JACC: Heart Failure"},{"issue":"11","key":"10.1002\/14651858.CD016183-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy","volume":"170","author":"Heitner","year":"2019","journal-title":"Annals of Internal Medicine"},{"issue":"10253","key":"10.1002\/14651858.CD016183-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD016183-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD016183-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD016183-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"Journal of the American College of Cardiology"},{"issue":"20","key":"10.1002\/14651858.CD016183-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD016183-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"issue":"21","key":"10.1002\/14651858.CD016183-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD016183-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","article-title":"Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4","volume":"30","author":"Masri","year":"2024","journal-title":"Journal of Cardiac Failure"},{"issue":"9","key":"10.1002\/14651858.CD016183-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.hlc.2023.05.019","article-title":"Efficacy and safety of mavacamten in the treatment of hypertrophic cardiomyopathy: a systematic review","volume":"32","author":"Bishev","year":"2023","journal-title":"Heart, Lung & Circulation"},{"issue":"1","key":"10.1002\/14651858.CD016183-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"101429","DOI":"10.1016\/j.cpcardiol.2022.101429","article-title":"Mavacamten treatment for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Ismayl","year":"2023","journal-title":"Current Problems in Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD016183-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2459\/JCM.0000000000001638","article-title":"Evaluation of mavacamten in patients with hypertrophic cardiomyopathy","volume":"25","author":"Liang","year":"2024","journal-title":"Journal of Cardiovascular Medicine (Hagerstown, Md.)"},{"issue":"10","key":"10.1002\/14651858.CD016183-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"FSO898","DOI":"10.2144\/fsoa-2023-0059","article-title":"Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"9","author":"Memon","year":"2023","journal-title":"Future Science OA"},{"key":"10.1002\/14651858.CD016183-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1190181","DOI":"10.3389\/fcvm.2023.1190181","article-title":"Comparing the efficacy and safety of medications in adults with hypertrophic cardiomyopathy: a systematic review and network meta-analysis","volume":"10","author":"Mi","year":"2023","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016183-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s43044-023-00328-7","article-title":"Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials","volume":"75","author":"Rabiee","year":"2023","journal-title":"Egyptian Heart Journal"},{"key":"10.1002\/14651858.CD016183-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s43044-023-00427-5","article-title":"Analyzing safety and effectiveness of mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis","volume":"75","author":"Rangwala","year":"2023","journal-title":"Egyptian Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD016183-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"e24207","DOI":"10.1002\/clc.24207","article-title":"A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy","volume":"47","author":"Sawan","year":"2024","journal-title":"Clinical Cardiology"},{"key":"10.1002\/14651858.CD016183-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.amjcard.2024.07.007","article-title":"Comparison of drug therapy efficacy in patients with hypertrophic cardiomyopathy: a network meta-analysis","volume":"226","author":"Shang","year":"2024","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD016183-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"e0301704","DOI":"10.1371\/journal.pone.0301704","article-title":"Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging","volume":"19","author":"Vyas","year":"2024","journal-title":"PLOS One"},{"issue":"2","key":"10.1002\/14651858.CD016183-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10741-023-10375-6","article-title":"A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy","volume":"29","author":"Yacoub","year":"2024","journal-title":"Heart Failure Reviews"},{"key":"10.1002\/14651858.CD016183-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.amjcard.2023.10.059","article-title":"The efficacy of cardiac myosin inhibitors versus placebo in patients with symptomatic hypertrophic cardiomyopathy: a meta-analysis and systematic review","volume":"210","author":"Yassen","year":"2024","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD016183-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"1477487","DOI":"10.3389\/fcvm.2024.1477487","article-title":"Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials","volume":"11","author":"Abunada","year":"2025","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016183-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"e003215","DOI":"10.1136\/openhrt-2025-003215","article-title":"Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Aman","year":"2025","journal-title":"Open Heart"},{"key":"10.1002\/14651858.CD016183-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amjcard.2025.01.016","article-title":"The efficacy and safety of cardiac myosin inhibitors versus placebo in patients with symptomatic obstructive hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials","volume":"241","author":"Ezenna","year":"2025","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD016183-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/2047487319828474","article-title":"Risk factors for atrial fibrillation in hypertrophic cardiomyopathy","volume":"28","author":"Philipson","year":"2021","journal-title":"European Journal of Preventive Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD016183-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"e0180064","DOI":"10.1371\/journal.pone.0180064","article-title":"MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy","volume":"12","author":"McNamara","year":"2017","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD016183-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mayocp.2023.11.019","article-title":"Genotype influences mavacamten responsiveness in obstructive hypertrophic cardiomyopathy","volume":"99","author":"Giudicessi","year":"2024","journal-title":"Mayo Clinic Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD016183-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jchf.2023.10.004","article-title":"Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design","volume":"12","author":"Coats","year":"2024","journal-title":"JACC: Heart Failure"},{"key":"10.1002\/14651858.CD016183-BIB0054|cit54","unstructured":"Phase 3 trial to evaluate the efficacy and safety of aficamten compared to metoprolol succinate in adults with symptomatic oHCM (MAPLE-HCM) https:\/\/clinicaltrials.gov\/study\/NCT05767346"},{"key":"10.1002\/14651858.CD016183-BIB0055|cit55","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD016183-BIB0056|cit56","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews (MECIR) https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016183-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016183-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016183-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jclinepi.2017.02.016","article-title":"Quasi-experimental study designs series \u2013 paper 5: a checklist for classifying studies evaluating the effects on health interventions \u2013 a taxonomy without labels","volume":"89","author":"Reeves","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016183-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"key":"10.1002\/14651858.CD016183-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s41669-022-00335-5","article-title":"Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): a new patient-reported outcome (PRO) instrument","volume":"6","author":"Reaney","year":"2022","journal-title":"PharmacoEconomics \u2013 Open"},{"key":"10.1002\/14651858.CD016183-BIB0062|cit62","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlejohn A Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016183-BIB0063|cit63","unstructured":"Peryer G Golder S Junqueira D Vohra S Loke YK Chapter 19: Adverse effects (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016183-BIB0064|cit64","unstructured":"Smith H Tavender E Klaes D Hinds P Remmington T Sparkes V Cochrane Register of Studies (CRS) https:\/\/training.cochrane.org\/resource\/tsc-induction-mentoring-training-guide\/3-cochrane-register-studies\/36-features-crs"},{"issue":"11","key":"10.1002\/14651858.CD016183-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000027.pub2","article-title":"Methods for obtaining unpublished data","author":"Young","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD016183-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/bmjebm-2019-111230","article-title":"What to do with a clinical trial with conflicts of interest","volume":"25","author":"Lundh","year":"2020","journal-title":"BMJ Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD016183-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jclinepi.2023.06.020","article-title":"A structured approach to information retrieval improved identification of funding and researchers' conflicts of interest in trials included in Cochrane reviews","volume":"161","author":"Faltinsen","year":"2023","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016183-BIB0068|cit68","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD016183-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016183-BIB0070|cit70","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016183-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD016183-BIB0072|cit72","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"15","key":"10.1002\/14651858.CD016183-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1161\/CIRCULATIONAHA.106.670901","article-title":"Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments","volume":"115","author":"Kosiborod","year":"2007","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD016183-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jchf.2022.03.003","article-title":"Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF","volume":"10","author":"Butler","year":"2022","journal-title":"JACC: Heart Failure"},{"key":"10.1002\/14651858.CD016183-BIB0075|cit75","unstructured":"Higgins JP Eldridge SM Tianjing L Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"issue":"7109","key":"10.1002\/14651858.CD016183-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016183-BIB0077|cit77","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (chapter last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016183-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"k3802","DOI":"10.1136\/bmj.k3802","article-title":"Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews","volume":"362","author":"Kirkham","year":"2018","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016183-BIB0079|cit79","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016183-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016183-BIB0081|cit81","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD016183-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy","volume":"79","author":"Maron","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"issue":"21","key":"10.1002\/14651858.CD016183-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"e012041","DOI":"10.1161\/JAHA.119.012041","article-title":"Impact of sex on clinical course and survival in the contemporary treatment era for hypertrophic cardiomyopathy","volume":"8","author":"Rowin","year":"2019","journal-title":"Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease"},{"issue":"7","key":"10.1002\/14651858.CD016183-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jclinepi.2014.02.008","article-title":"Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study","volume":"67","author":"Schmidt","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD016183-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11121-013-0377-7","article-title":"Meta-analysis and subgroups","volume":"14","author":"Borenstein","year":"2013","journal-title":"Prevention Science"},{"issue":"1","key":"10.1002\/14651858.CD016183-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O'Neill","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016183-BIB0087|cit87","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016183-BIB0088|cit88","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Alk EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016183-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T10:21:47Z","timestamp":1750674107000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016183"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":89,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016183","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}